Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2017 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.
Keizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Wolf I, Geva R, Margel D, Rouvinov K, Stern A, Dresler H, Kushnir I, Eliaz I. Keizman D, et al. Nutrients. 2023 Aug 11;15(16):3533. doi: 10.3390/nu15163533. Nutrients. 2023. PMID: 37630724 Free PMC article. Clinical Trial.
Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol()-Modified citrus pectin (P-MCP) is a food supplement categorized as GRAS (Generally Recognized As Safe) by the FDA. ...After a total of 18 months of P-MCP treatment, 8 …
Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol()-Modified citrus pectin (P- …
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Margel D, Wolf I, Geva R, Dresler H, Rouvinov K, Rapoport N, Eliaz I. Keizman D, et al. Nutrients. 2021 Nov 28;13(12):4295. doi: 10.3390/nu13124295. Nutrients. 2021. PMID: 34959847 Free PMC article. Clinical Trial.
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol(), P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a carbohydrate-binding protein …
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Guess BW, et al. Prostate Cancer Prostatic Dis. 2003;6(4):301-4. doi: 10.1038/sj.pcan.4500679. Prostate Cancer Prostatic Dis. 2003. PMID: 14663471 Clinical Trial.
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cr …
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cance …
Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study.
Ried K, Eng P, Sali A. Ried K, et al. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2275-2285. doi: 10.22034/APJCP.2017.18.8.2275. Asian Pac J Cancer Prev. 2017. PMID: 28843267 Free PMC article.
Follow-up tests including scans, scheduled within 1-10 months of positive CTC tests, found early cancerous lesions in 20% of screened patients. In 50% of male patients with CTC and normal PSA (prostate-specific-antigen) levels, PSMA-PET scans revealed increased uptake in t …
Follow-up tests including scans, scheduled within 1-10 months of positive CTC tests, found early cancerous lesions in 20% of screened patien …